Evidence map›Paper›PMID 24138531›Full record

ArticleBiochemistry2013

Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11.

Katheryne Z Edson, Bhagwat Prasad, Jashvant D Unadkat, Yoshitomo Suhara, Toshio Okano, F Peter Guengerich, Allan E Rettie

Abstract read
In one paragraph

Article in Biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Cytochrome P450 FamilyACS pharmacology & translational science · 2024
    Article
  10. Article
  11. Review
  12. Human Orphan Cytochromes P450: An Update.Current drug metabolism · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Katheryne Z EdsonDepartment of Medicinal Chemistry and ‡Department of Pharmaceutics, School of Pharmacy at the University of Washington , Box 357610, Seattle, Washington 98105, United States.
Bhagwat Prasad
Jashvant D Unadkat
Yoshitomo Suhara
Toshio Okano
F Peter Guengerich
Allan E Rettie
Kobe Pharmaceutical University · JPUniversity of Washington · USYokohama University of Pharmacy · JPVanderbilt University · US

Funding

Pharmacogenetics in Rural and Underserved PopulationsU01GM092676 · NIGMS · UNIVERSITY OF WASHINGTON · PI BURKE, WYLIE G., THUMMEL, KENNETH E. · 2010 to 2014
$9.9M
Metabolism of Carcinogens and Drugs by Human P450sR37CA090426 · NCI · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 2006 to 2015
$3.6M
Pharmacogenetics of ADRs: Warfarin ToxicityR01GM068797 · NIGMS · UNIVERSITY OF WASHINGTON · PI RETTIE, ALLAN EDWARD · 2004 to 2010
$2.3M
New Vistas in Vitamin K MetabolismR01GM109743 · NIGMS · UNIVERSITY OF WASHINGTON · PI RETTIE, ALLAN EDWARD · 2013 to 2016
$1.1M
NCI NIH HHS R37 CA090426NIGMS NIH HHS R01 GM068797NIGMS NIH HHS R01 GM109743NIGMS NIH HHS U01 GM092676NIGMS NIH HHS U01 GM92676
6 · The paper itself

Abstract

Vitamin K plays an essential role in many biological processes including blood clotting, maintenance of bone health, and inhibition of arterial calcification. A menaquinone form of vitamin K, MK4, is increasingly recognized for its key roles in mitochondrial electron transport, as a ligand for the nuclear receptor SXR, which controls the expression of genes involved in transport and metabolism of endo- and xenobiotics, and as a pharmacotherapeutic in the treatment of osteoporosis. Although cytochrome P450 (CYP) 4F2 activity is recognized as an important determinant of phylloquinone (K1) metabolism, the enzymes involved in menaquinone catabolism have not been studied previously. CYP4F2 and CYP4F11 were expressed and purified and found to be equally efficient as in vitro catalysts of MK4 ω-hydroxylation. CYP4F2, but not CYP4F11, catalyzed sequential metabolism of MK4 to the ω-acid without apparent release of the intermediate aldehyde. The ω-alcohol could also be metabolized to the acid by microsomal NAD(+)-dependent alcohol and aldehyde dehydrogenases. LC-MS/MS analysis of trypsinized human liver microsomes (using a surrogate peptide approach) revealed the mean concentrations of CYP4F2 and CYP4F11 to be 14.3 and 8.4 pmol/mg protein, respectively. Microsomal MK4 ω-hydroxylation activities correlated with the CYP4F2 V433M genotype but not the CYP4F11 D446N genotype. Collectively, these data expand the lexicon of vitamin K ω-hydroxylases to include the 'orphan' P450 CYP4F11 and identify a common variant, CYP4F2 (rs2108622), as a major pharmacogenetic variable influencing MK4 catabolism.

Indexed as

Cytochrome P-450 CYP4ACytochrome P-450 Enzyme SystemCytochrome P450 Family 4HumansHydroxylationKineticsMicrosomes, LiverVitamin K 2CYP4F11 protein, humanCYP4F2 protein, humanCytochrome P-450 CYP4ACytochrome P-450 Enzyme SystemCytochrome P450 Family 4menatetrenoneVitamin K 2

Identifiers

PMID24138531
PMCPMC3900248
OpenAlexW2136240627

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.